Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reiberger

Showing results (421-430 of 491) with videos related to

Pageof 50
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2026
Stage-specific drivers of clinical progression in advanced chronic liver diseaseBenedikt Simbrunner, Georg Semmler, Marta Bofill Roig, et al.
Journal of Hepatology|February 17, 2020
HDL-related biomarkers are robust predictors of survival in patients with chronic liver failureMarkus Trieb, Florian Rainer, Vanessa Stadlbauer, et al.
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2026
Post-TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS PlacementMarlene Hintersteininger, Simon Johannes Gairing, Katrin Kirsch, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 4, 2025
The Vasopressin Biomarker Copeptin is Linked to Systemic Inflammation and Refines Prognostication in Decompensated CirrhosisLukas Hartl, Marlene Hintersteininger, Benedikt Simbrunner, et al.
Hepatology (Baltimore, Md.)|March 6, 2024
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertensionGeorg Semmler, Lukas Hartl, Yuly Paulin Mendoza, et al.
Pageof 50

Showing results (421-430 of 491) with videos related to

Sort By:
Pageof 50
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2026
Stage-specific drivers of clinical progression in advanced chronic liver diseaseBenedikt Simbrunner, Georg Semmler, Marta Bofill Roig, et al.
Journal of Hepatology|February 17, 2020
HDL-related biomarkers are robust predictors of survival in patients with chronic liver failureMarkus Trieb, Florian Rainer, Vanessa Stadlbauer, et al.
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2026
Post-TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS PlacementMarlene Hintersteininger, Simon Johannes Gairing, Katrin Kirsch, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 4, 2025
The Vasopressin Biomarker Copeptin is Linked to Systemic Inflammation and Refines Prognostication in Decompensated CirrhosisLukas Hartl, Marlene Hintersteininger, Benedikt Simbrunner, et al.
Hepatology (Baltimore, Md.)|March 6, 2024
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertensionGeorg Semmler, Lukas Hartl, Yuly Paulin Mendoza, et al.
Pageof 50